Aspartate-beta-hydroxylase Induces Epitope-specific T Cell Responses in Tumors

Abstract

The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.

1 . A composition comprising a therapeutically effective amount of a purified aspartate-β-hydroxylase (ASPH) peptide, wherein said peptide comprises at least 7 amino acids in length and fewer amino acids than the full length ASPH protein and wherein said peptide comprises an HLA class I or class II-restricted epitope sequence. 
     
     
         2 . The composition of  claim 1 , wherein the peptide comprises the HLA class II restricted sequence of TGYTELVKSLERNWKLI (SEQ ID NO:11). 
     
     
         3 . The composition of  claim 1 , wherein the peptide comprises the HLA class I restricted sequence of YPQSPRARY (SEQ ID NO:26). 
     
     
         4 . The composition of  claim 1 , wherein the peptide is selected from the group consisting of SEQ ID NOs: 1-45. 
     
     
         5 . The composition of  claim 1 , further comprising a pharmaceutical carrier, adjuvant or other co-ingredient. 
     
     
         6 . A vaccine comprising the composition of  claim 1 . 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled)